公开(公告)号：US20220168357A1

公开(公告)日：2022-06-02

申请号：US17602421

申请日：2020-04-09

Applicant: Orizuru Therapeutics, Inc.

Inventor： Hideyuki HIYOSHI ,  Taisuke MOCHIDA ,  Noriko YAMAZOE ,  Junji YAMAURA ,  Taro TOYODA ,  Shuhei KONAGAYA

IPC: A61K35/39 ,  C12N5/071 ,  A61P3/10

Abstract: An object of the present invention is to provide a novel method for producing a biological tissue-like structure comprising differentiated cells induced from pluripotent stem cells, and the present invention provides a method of forming a biological tissue-like structure together with host-derived blood vessels and connective tissue by transplanting a composition in which cells derived from pluripotent stem cells are disposed to be dispersed in a biocompatible material to induce the differentiation of the cells.

公开(公告)号：US11324777B2

公开(公告)日：2022-05-10

申请号：US15825275

申请日：2017-11-29

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair Reisner ,  Yaki Eidelstein ,  Eran Ophir ,  Assaf Lask ,  Ran Afik ,  Noga Or-Geva ,  Esther Bachar-Lustig

IPC: A61K35/17 ,  A61K39/00 ,  C12N5/0783 ,  A61K35/22 ,  A61K35/26 ,  A61K35/28 ,  A61K35/34 ,  A61K35/36 ,  A61K35/38 ,  A61K35/39 ,  A61K35/407 ,  A61K35/42 ,  A61K35/12

Abstract: A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.

公开(公告)号：US11287427B2

公开(公告)日：2022-03-29

申请号：US16620747

申请日：2018-06-11

Applicant: VANDERBILT UNIVERSITY ,  THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS

Inventor： Alvin C. Powers ,  Marcela Brissova ,  Chunhua Dai ,  Neil Phillips ,  Diane Saunders

IPC: G01N33/573 ,  A61K35/39 ,  G01N33/569 ,  C07K16/40 ,  G01N33/543

Abstract: In spite of significant efforts to identify β-cell-specific markers for β-cell imaging and purification, progress has been limited. Herein is disclosed a novel biomarker of human pancreatic β-cells, CD39L3 (also known as ectonucleoside triphosphate diphosphohydrolase-3 (NTPDase3)). Disclosed are compositions and methods for purifying and imaging β-cell using anti-CD39L3 antibodies.

公开(公告)号：US20220072061A1

公开(公告)日：2022-03-10

申请号：US17298017

申请日：2019-11-25

Applicant: Futian Dong

Inventor： Futian Dong

IPC: A61K35/30 ,  A61K35/32 ,  A61K35/42 ,  A61K35/407 ,  A61K36/47 ,  A61K35/22 ,  A61K35/39 ,  A61P25/24 ,  A61P15/12 ,  A61P9/10 ,  A61P19/02 ,  A61P11/06 ,  A61P11/02 ,  A61P27/02 ,  A61P37/08 ,  A61P9/12 ,  A61P3/10

Abstract: The present disclosure provides a substance for treatment and/or prevention of diseases, the method for designing the substance, and the method for preparing the substance. A stable structure corresponding to a substance associated with diseases is used as the substance for treatment or prevention of the diseases. The essence of disease is the imbalance of the biological structure system. The structural imbalance of different substances will cause different diseases. The present invention discloses that the biological body recognizes the stable structure corresponding to the substance, adjusts its gene or gene expression by the self-adaptation and self-organization functions of its own structural system, and restores the biological structure system to be related to the substance. The balance of structure, treatment and/or prevention of diseases related to the substance.

公开(公告)号：US20220000934A1

公开(公告)日：2022-01-06

申请号：US17309176

申请日：2019-11-04

Applicant: Figene, LLC

Inventor： Pete O'Heeron ,  Thomas Ichim

IPC: A61K35/33 ,  A61K35/39 ,  A61K35/44 ,  A61K35/50 ,  A61P3/08

Abstract: Embodiments of the disclosure pertain to the treatment of diabetes through replacement of insulin producing cells. In specific embodiments, the disclosure encompasses the use of cellular adjuvants to enhance survival, engraftment and tolerogenesis of insulin-producing cells. In certain cases the disclosure concerns the manipulation of a hepatic microenvironment to promote immunological tolerance at an enhanced level to allow for integration of allogeneic insulin-producing cells. Particular embodiments utilize fibroblasts to enhance immunological tolerance for insulin-producing cells upon engraftment.

公开(公告)号：US20210403874A1

公开(公告)日：2021-12-30

申请号：US17285038

申请日：2019-10-11

Applicant: Evia Life Sciences Inc.

Inventor： Takahiro Ochiya ,  Juntaro MATSUZAKI ,  Hideharu ENOMOTO ,  Masumi SHINOHARA

IPC: C12N5/071 ,  G01N33/50 ,  A61K35/39

Abstract: The present invention provides a method starting from cells derived from a mammalian endodermal tissue or organ (except for the liver) to produce stein/progenitor cells thereof, which comprises bringing the cells derived from the endodermal tissue or organ into contact in vitro with a TGFβ-receptor inhibitor.

公开(公告)号：US11207444B2

公开(公告)日：2021-12-28

申请号：US16847220

申请日：2020-04-13

Applicant: SERNOVA CORP.

Inventor： Jeffrey Hubbell ,  Alice Tomei

IPC: A61L27/34 ,  A61K47/10 ,  C12N5/00 ,  A61K9/00 ,  A61K9/06 ,  A61K9/48 ,  A61K9/20 ,  A61K35/39 ,  A61L27/36

Abstract: Hydrodynamic methods for conformally coating non-uniform size cells and cell clusters for implantation, thus preventing immune rejection or inflammation or autoimmune destruction while preserving cell functionality. A method for conformally coating cells and c clusters with hydrogels that are biocompatible, mechanically and chemically stable and porous, with an appropriate pore cut-off size. The methods of the invention are advantageously reproducible and result in a relatively high yield of coated versus non-coated cell clusters, without compromising cell functionality. Conformal coating devices configured to perform the methods of the invention, methods of optimally utilizing said devices and purifying the coated islets, and coated biomaterials made by said methods.

公开(公告)号：US20210369788A1

公开(公告)日：2021-12-02

申请号：US16762829

申请日：2018-11-08

Applicant: ANIMAL CELL THERAPY - ACT

Inventor： Paul CZERNICHOW

IPC: A61K35/39 ,  C12N5/071 ,  A61K47/69

Abstract: The present invention relates to an in vitro method for preparing and producing canine pancreatic islets from immature pancreatic tissue. Such islets express, produce and secrete insulin upon glucose stimulation. The invention further encompasses canine pancreatic islets obtainable according to the present method, islet population of said islets and compositions comprising said islets. It also relates to transduced canine pancreatic islets, or tumours or cells derived thereof. The present invention also concerns the use of said canine pancreatic islets or cells derived thereof for treating a canine pancreatic disorder, such as canine diabetes, or for diagnosing canine diabetes.

公开(公告)号：US20210355449A1

公开(公告)日：2021-11-18

申请号：US17222833

申请日：2021-04-05

Applicant: SDF BioPharma Inc.

Inventor： Gerald F. Swiss ,  David Kiewlich

IPC: C12N5/071 ,  A61P3/10 ,  A61K35/17 ,  C12N5/0783 ,  C12N5/0781 ,  A61K35/39 ,  C07K14/52

Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.

公开(公告)号：US11141508B2

公开(公告)日：2021-10-12

申请号：US16289626

申请日：2019-02-28

Applicant: Seraxis, Inc.

Inventor： William L Rust

IPC: A61K35/39 ,  A61L31/08 ,  A61P3/10 ,  A61L31/04 ,  A61P5/48 ,  A61P5/50 ,  A61L27/38 ,  A61L27/54 ,  A61K9/50 ,  A61K35/00

Abstract: Described are macro-capsules, barriers, and devices that can be used to prepare therapeutic cell implants, methods of encapsulating therapeutic cells, and methods of using the encapsulated cells in the treatment of disease.